Intravitreal Bevacizumab vs Photocoagulation for Proliferative Diabetic Retinopathy

Sponsor
Asociación para Evitar la Ceguera en México
Study ID
NCT00347698
Phase
PHASE2/PHASE3
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of the study is to evaluate the safety and efficacy of 2.5 mg of intravitreal bevacizumab in one eye, versus panretinal photocoagulation in the contralateral eye, for the treatment of patients with untreated symmetric proliferative diabetic retinopathy.

Key Dates

First listed
Jul 4, 2006
Start date
Mar 31, 2006
Status verified
May 2024
Primary completion
Mar 31, 2006
Completion
Aug 31, 2007

Study Design

Enrollment
0 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Primary Outcome Measure

Best corrected visual acuity at six months and one year

Related Studies